Renaissance Technologies LLC raised its holdings in Savara Inc. (NASDAQ:SVRA – Free Report) by 96.5% in the 1st quarter, HoldingsChannel reports. The fund owned 652,672 shares of the company’s stock after acquiring an additional 320,572 shares during the period. Renaissance Technologies LLC’s holdings in Savara were worth $3,564,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. Prudential Financial Inc. acquired a new stake in shares of Savara during the second quarter worth $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP purchased a new position in Savara during the second quarter worth about $33,000. Russell Investments Group Ltd. lifted its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in Savara in the 3rd quarter valued at about $44,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Savara Stock Performance
NASDAQ:SVRA opened at $5.83 on Friday. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -10.41 and a beta of 0.29. The firm’s fifty day simple moving average is $5.62 and its 200 day simple moving average is $5.50. Savara Inc. has a twelve month low of $2.43 and a twelve month high of $7.01.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Oppenheimer began coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.
Check Out Our Latest Research Report on SVRA
Savara Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Recommended Stories
- Five stocks we like better than Savara
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
